Lipigon Q3 2022 - Safety Demonstrated in the SAD Part with Lipisense
2022-11-24 13:44:00
Redeye comments on Lipigon's third quarter report, in particular on the SAD and recently initiated MAD part of the phase I trial with Lipisense and on the financial situation.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.